New drug combo aims to make bone marrow transplants safer
NCT ID NCT04395222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the drug tocilizumab to a standard transplant regimen can prevent graft failure and graft-versus-host disease in people with blood cancers receiving a special type of bone marrow transplant. The study involves 21 participants and aims to replace a stronger immune-suppressing drug to improve recovery and reduce relapse. Results will be tracked for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tocilizumab (also called Actemra)
- What this could lead to
- If successful, this could make haplo-cord transplants safer and more effective for people with blood cancers, reducing complications like graft failure and graft-versus-host disease.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply broadly. The drug may not prevent graft failure or GVHD as hoped, and there are risks from the transplant itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTOID DENDRITIC CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medical College
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Frailty check may steer safer cancer care for seniors